Moleculin Biotech (MBRX) announced new findings supporting the ability of Annamycin to overcome resistance to Venetoclax in acute myeloid leukemia. This includes data from preclinical in vitro studies recently accepted for online publication at the upcoming American Society of Hematology, ASH, Annual Meeting, and correlates with efficacy demonstrated by recent preliminary clinical data in subjects who were relapsed from or refractory to first line Venetoclax regimens and were then treated with Annamycin in combination with Ara-C. Preclinical data accepted for online publication at ASH Annual Meeting reveal significant activity of Annamycin in Venetoclax resistant AML model. New preliminary clinical results show Annamycin plus Ara-C achieved 60% CR/CRi in subjects who were relapsed from or refractory to Venetoclax regimens; more than 4 times greater than published historical rates. Annamycin demonstrates an even greater potential than previously reported to address a significant AML patient population for which treatment options are extremely limited. New data from MB-106 trial show median overall survival of 11.6 months in subjects receiving AnnAraC as 2nd line therapy
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MBRX:
- Moleculin Biotech Unveils New Corporate Presentation
- Moleculin Biotech Accelerates Annamycin Phase 3 Trial
- Moleculin Biotech accelerates unblinding of Phase 3 efficacy data in AML
- Moleculin Biotech Gains IRB Approval for Phase 3 Trial
- Moleculin Biotech’s Phase 3 trial of Annamycin approved by Review Board
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
